Parallel evolution of OA phenotypes and therapies

Nature Reviews Rheumatology

Volumn 9, Issue 2, 2013, Pages 68-70

  Conaghan, Philip G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; KARTOGENIN; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

BONE MARROW DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG COST; DRUG EFFICACY; HUMAN; KNEE OSTEOARTHRITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; ANIMAL; BONE MARROW; CATTLE; DISEASE MODEL; DRUG ANTAGONISM; MOUSE; PATHOLOGY;

ANIMALS; ANTIRHEUMATIC AGENTS; BONE MARROW; CATTLE; DISEASE MODELS, ANIMAL; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; OSTEOARTHRITIS; PHENOTYPE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873411377     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.225     Document Type: Review

References (10)

1. Zhang, W. et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18, 476-499 (2010).
2. Wenham, C. Y. & Conaghan, P. G. Imaging the painful osteoarthritic knee joint: what have we learned? Nat. Clin. Pract. Rheumatol. 5, 149-158 (2009).
3. Sellam, J. & Berenbaum, F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat. Rev. Rheumatol. 6, 625-635 (2010).
4. Maksymowych, W. P. et al. Targeting tumor necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. Arthritis Res. Ther. 14, R206 (2012).
5. Verbruggen, G., Wittoek, R., Vander Cruyssen, B. & Elewaut, D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann. Rheum. Dis. 71, 891-898 (2012).
6. Kortekaas, M. C., Kwok, W. Y., Reijnierse, M., Huizinga, T. W. & Kloppenburg, M. In erosive hand osteoarthritis more inflammatory signs on ultrasound are found than in the rest of hand osteoarthritis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2012-201458.
7. Laslett, L. L. et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann. Rheum. Dis. 71, 1322-1328 (2012).
8. Guermazi, A. et al. Prevalence of abnormalities in knees detected by MRI in adults without knee osteoarthritis: population based observational study (Framingham Osteoarthritis Study). BMJ 345, e5339 (2012).
9. Studer, D., Millan, C., Öztürk, E., Maniura-Weber, K. & Zenobi-Wong, M. Molecular and biophysical mechanisms regulating hypertrophic differentiation in chondrocytes and mesenchymal stem cells. Eur. Cell. Mater. 24, 118-135 (2012).
10. Johnson, K. et al. A stem cell-based approach to cartilage repair. Science 336, 717-721 (2012).